Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: A comparison with conventional dosage

Leukemia

Volumn 15, Issue 5, 2001, Pages 735-741

  Shen, Y ^a   Shen, Z X ^a   Yan, H ^a   Chen, J ^a   Zeng, X Y ^a   Li, J M ^a   Li, X S ^a   Wu, W ^a   Xiong, S M ^a   Zhao, W L ^a   Tang, W ^a   Wu, F ^a   Liu, Y F ^a   Niu, C ^a   Wang, Z Y ^a   Chen, S J ^a   Chen, Z ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Acute promyelocytic leukemia; Apoptosis; Arsenic trioxide; Differentiation; Pharmacokinetics; Survival

Indexed keywords

ARSENIC TRIOXIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD; BONE MARROW; BONE MARROW BIOPSY; CANCER RECURRENCE; CANCER REGRESSION; CARDIOTOXICITY; CELL DIFFERENTIATION; CHILD; CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL RESEARCH; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; FACE EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER FAILURE; MALE; MOUTH ULCER; PHARMACOKINETICS; PRIORITY JOURNAL; RASH;

EID: 0035007005     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402106     Document Type: Article

References (22)

1. Therapy of acute promyelocytic leukemia: All-trans retinoic acid and beyond
2. Acute promyelocytic leukemia: Cellular and molecular basis of differentiation and apoptosis
3. The PML and PML/RARalpha domains: From autoimmunity to molecular oncology and from retinoic acid to arsenic
4. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients
5. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As203: An experience of 120 patients at a single institution
6. Current issues in the management of acute promyelocytic leukemia
7. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
8. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: Clinical and basic studies for the next generation
9. 3 experts dose-dependent dual effects on APL cells
10. 3) on acute promyelocytic leukemic cell line
11. Acute and chronic arsenic poisoning associated with treatment of acute promyelocytic leukemia
12. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
13. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 2 expression and PML-RAR alpha/PML proteins
14. Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents
15. The thrombophilic state in acute promyelocytic leukemia
16. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells
17. PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia
18. Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia
19. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RA Ralpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient
20. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
21. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner
22. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations